Synthesis of phycoerythrin-Ag-ZnO nanobiocomposite from marine red algae Porphyridium purpureum for anticancer applications against MCF-7 cell line
Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/64016
metadata.dc.identifier.doi:
https://doi.org/10.56042/ijeb.v62i06.3807Title: Synthesis of phycoerythrin-Ag-ZnO nanobiocomposite from marine red algae Porphyridium purpureum for anticancer applications against MCF-7 cell lineAuthors:
G, BaskarK, KeerthanaA, SupriyaR, PravinAR, AbineshSA, YuvaraajKeywords: Bimetallic nanoparticles;Cancer;Chemotherapy;Red seaweedIssue Date: Jun-2024Publisher: NIScPR-CSIR,IndiaAbstract: The focus on utilization of marine macroalgae for green synthesis of bimetallic nanoparticles with potential applications
in cancer treatment has gained a lot of attention in recent years. In this present study, we synthesized a nanobiocomposite
using the red pigment R-phycoerythrin from the marine red algae Porphyridium purpureum and explored its anticancer
potential. This vibrant red fluorescent pigment plays a crucial role as a reducing and stabilizing agent. Ag-ZnO
nanobiocomposite was synthesized by green approach using phycoerythrin as a capping agent. The synthesized
nanobiocomposite was characterized using UV-Vis spectroscopy, XRD, FT-IR and SEM-EDX techniques. The obtained
UV-Vis graph has confirmed the presence of Ag, Zn and phycoerythrin in the synthesized nanobiocomposite. The FT-IR
showed the occurrence of Zn–O vibration peak along with hydroxyl and carboxyl groups. The XRD results confirmed the
crystalline nature and hexagonal shape of the nanobiocomposite. The overall effect of the synthesized phycoerythrin-Ag-
ZnO nanobiocomposite was studied by MTT assay to check its anticancer applications. From the obtained results, the IC50
value was found to be 100 μg against MCF-7 cell line. This confirms that the synthesized phycoerythrin-Ag-ZnO
nanobiocomposite inhibited the growth of MCF-7 cell line and thus can be efficiently used as a photosensitive drug for
chemotherapy in future.Page(s): 393-399ISSN: 0975-1009 (Online); 0019-5189 (Print)Appears in Collections:
IJEB Vol.62(06) [June 2024]Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.
留言 (0)